上海谊众发预增，预计2025年度归母净利润同比增长760.18%到903.54%

Core Viewpoint - Shanghai Yizhong (688091.SH) forecasts a net profit attributable to shareholders of the parent company for 2025 to be between 60 million and 70 million yuan, representing a growth of 760.18% to 903.54% compared to the same period last year [1] Group 1: Financial Performance - The expected net profit for 2025 is projected to be between 60 million and 70 million yuan [1] - This represents a significant increase of 760.18% to 903.54% compared to the previous year [1] Group 2: Key Drivers of Performance - The primary reason for the performance change is the inclusion of the company's core product, paclitaxel polymer micelles, in the national medical insurance catalog in 2025 [1] - This inclusion is expected to significantly enhance market access and the number of patients using the product, leading to substantial growth in revenue and profit compared to 2024 [1]